Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Potent EGFR-kinase inhibitor (IC50 = 0.7 nM). Displays <3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 35 days | $ 578.00 |
Description | Potent EGFR-kinase inhibitor (IC50 = 0.7 nM). Displays >3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable. |
Targets&IC50 | EGFR tyrosine kinase:0.7 nM (IC50) |
Molecular Weight | 366.85 |
Formula | C20H19ClN4O |
CAS No. | 2230253-82-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PKI-166 hydrochloride 2230253-82-2 PKI166 Hydrochloride PKI-166 Hydrochloride PKI 166 hydrochloride PKI166 hydrochloride PKI 166 Hydrochloride inhibitor inhibit